Exscientia PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EXAI Nasdaq 8731 https://www.exscientia.ai/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Exscientia PLC (ADR)

Q4 2022 Exscientia PLC Earnings Call - Mar 24th, 2023 4:58 am
Exscientia Business and Financial Update for the Full Year 2022 - Mar 23rd, 2023 11:00 am
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023 - Mar 16th, 2023 11:00 am
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR - Mar 15th, 2023 11:00 am
Exscientia Announces Expansion of its Precision Oncology Pipeline - Mar 14th, 2023 11:00 am
Exscientia (NASDAQ:EXAI) shareholders have endured a 55% loss from investing in the stock a year ago - Mar 10th, 2023 1:38 pm
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform - Mar 7th, 2023 12:00 pm
Exscientia to Present at Upcoming Investor Conferences in March - Feb 22nd, 2023 1:00 pm
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318 - Feb 2nd, 2023 1:00 pm
Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans - Jan 20th, 2023 2:23 pm
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress - Dec 6th, 2022 12:00 pm
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours - Nov 28th, 2022 12:00 pm
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates - Nov 15th, 2022 2:45 pm
Exscientia Business and Financial Update for the Third Quarter 2022 - Nov 15th, 2022 1:00 pm
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments - Nov 14th, 2022 12:00 pm
Institutions own 27% of Exscientia plc (NASDAQ:EXAI) shares but individual investors control 57% of the company - Nov 11th, 2022 11:33 am
Evotec falls as U.K. writedown, expansion costs drive 9-month loss - Nov 9th, 2022 4:02 am
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022 - Nov 8th, 2022 12:00 pm
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Misses Revenue Estimates - Nov 3rd, 2022 9:35 pm
Exscientia Expands Biologics Design Capability with Automated Laboratory - Nov 3rd, 2022 11:00 am